{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T13:33:24Z","timestamp":1789133604905,"version":"build-2803163510"},"reference-count":28,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2022,10,21]],"date-time":"2022-10-21T00:00:00Z","timestamp":1666310400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In the long-term extension study of the ERASURE and FIXTURE trials, the efficacy of secukinumab (a fully human anti-interleukin-17A monoclonal antibody) was demonstrated to have been maintained through to year 3 of treatment in moderate-to-severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the efficacy and safety of secukinumab through to year 5 of treatment in moderate-to-severe plaque psoriasis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Responders with \u2265 75% improvement in Psoriasis Area and Severity Index (PASI 75) from two core trials \u2013 ERASURE and FIXTURE \u2013 were randomized 2 : 1 at year 1 (end of core trials) to either the same dose (300 or 150\u2005mg, continuous treatment) or placebo (treatment withdrawal) every 4 weeks, until year 3 or relapse (&amp;gt; 50% reduction in maximal PASI from core study baseline). Partial responders (achieving PASI 50 but not PASI 75) at year 1 continued at the same dose as in the core trials. At year 3, all patients received open-label secukinumab treatment, with those on secukinumab 300\u2005mg continuing on their dose, while those on secukinumab 150\u2005mg or placebo received secukinumab 150 or 300\u2005mg based on the physician\u2019s discretion. The study is registered on ClinicalTrials.gov with the identifier NCT01544595.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Most patients randomized to placebo at year 1 relapsed, but the response was rapidly recaptured upon reinitiation of treatment. PASI responses were sustained with secukinumab through to year 5. The PASI responses for the 300\u2005mg responders + partial responders group at year 1 (PASI 75\/90\/100: 86.8%\/72.8%\/45.9%) trended downwards until year 3 (PASI 75\/90\/100: 82.3%\/58.4%\/32.7%) and then remained stable through year 4 (PASI 75\/90\/100: 83.3%\/60.1%\/32.2%) until year 5 (PASI 75\/90\/100: 81.1%\/62.8%\/35.1%). Dermatology Life Quality Index showed sustained benefit up to year 5. Absolute PASI responses were maintained throughout the study. The most common adverse events (AEs) were infections and infestations, nasopharyngitis, and upper respiratory tract infections (URTIs). The overall exposure-adjusted incidence rate (EAIR; with 95% confidence interval) for all AEs was 139.9 (130.3\u2013149.9). EAIRs for Crohn's disease and neutropenia were 0.1 (0.0\u20130.3) and 0.5 (0.3\u20130.8), respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The 4-year extension of two pivotal phase III trials demonstrated that secukinumab treatment was effective through to year 5 and improved quality of life in patients with moderate-to-severe plaque psoriasis. The most common AEs were infections and infestations, nasopharyngitis, and URTIs. The safety profile was consistent with that in the secukinumab phase II\/III clinical development programme.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/bjd\/ljac040","type":"journal-article","created":{"date-parts":[[2023,1,7]],"date-time":"2023-01-07T23:04:42Z","timestamp":1673132682000},"page":"198-207","source":"Crossref","is-referenced-by-count":53,"title":["Secukinumab long-term efficacy and safety in psoriasis through to year 5 of treatment: results of a randomized extension of the phase III ERASURE and FIXTURE trials"],"prefix":"10.1093","volume":"188","author":[{"given":"Richard G","family":"Langley","sequence":"first","affiliation":[{"name":"Dalhousie University , Halifax, NS , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7789-6915","authenticated-orcid":false,"given":"Howard","family":"Sofen","sequence":"additional","affiliation":[{"name":"Department of Medicine (Dermatology) UCLA , Los Angeles, CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio","family":"Dei-Cas","sequence":"additional","affiliation":[{"name":"Facultad de Medicina de la Universidad de Buenos Aires , Buenos Aires , Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5248-4332","authenticated-orcid":false,"given":"Kristian","family":"Reich","sequence":"additional","affiliation":[{"name":"Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing, University Medical Center Hamburg-Eppendorf , Hamburg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bardur","family":"Sigurgeirsson","sequence":"additional","affiliation":[{"name":"University of Iceland , Reykjavik , Iceland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2918-6481","authenticated-orcid":false,"given":"Richard B","family":"Warren","sequence":"additional","affiliation":[{"name":"Centre for Dermatology Research, University of Manchester , Manchester , UK"},{"name":"Salford Royal NHS Foundation Trust , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0165-5263","authenticated-orcid":false,"given":"Carle","family":"Paul","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Paul Sabatier University , Toulouse , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0766-6342","authenticated-orcid":false,"given":"Jacek C","family":"Szepietowski","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Venereology and Allergology, Wroclaw Medical University , Wroclaw , Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1498-1474","authenticated-orcid":false,"given":"Tsen-Fang","family":"Tsai","sequence":"additional","affiliation":[{"name":"National Taiwan University Hospital , Taipei , Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Hampele","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruquan","family":"You","sequence":"additional","affiliation":[{"name":"China Novartis Institutes for BioMedical Research , Shanghai , China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Charef","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charis","family":"Papavassilis","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG , Basel , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,10,21]]},"reference":[{"key":"2023100520314718800_ljac040-B1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S0140-6736(14)61909-7","article-title":"Psoriasis","volume":"386","author":"Boehncke","year":"2015","journal-title":"Lancet"},{"key":"2023100520314718800_ljac040-B2","author":"COSENTYX (secukinumab) [summary of product characteristics]","year":"2017"},{"key":"2023100520314718800_ljac040-B3","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jaad.2015.05.013","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial","volume":"73","author":"Tha\u00e7i","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2023100520314718800_ljac040-B4","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis \u2013 results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N Engl J Med"},{"issue":"6 Suppl. 1","key":"2023100520314718800_ljac040-B5","first-page":"S3","article-title":"The role of IL-17 in the pathogenesis and treatment of psoriasis","volume":"9","author":"Zeichner","year":"2016","journal-title":"J Clin Aesthet Dermatol"},{"key":"2023100520314718800_ljac040-B6","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1056\/NEJMoa1505066","article-title":"Secukinumab, an interleukin-17A inhibitor, in ankylosing spondylitis","volume":"373","author":"Baeten","year":"2015","journal-title":"N Engl J Med"},{"key":"2023100520314718800_ljac040-B7","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1016\/S0140-6736(15)61134-5","article-title":"Secukinumab, a human anti-interleukin-17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"386","author":"McInnes","year":"2015","journal-title":"Lancet"},{"key":"2023100520314718800_ljac040-B8","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1111\/1346-8138.14761","article-title":"Long-term efficacy and safety of secukinumab in Japanese patients with moderate to severe plaque psoriasis: 3-year results of a double-blind extension study","volume":"46","author":"Okubo","year":"2019","journal-title":"J Dermatol"},{"key":"2023100520314718800_ljac040-B9","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1111\/jdv.14878","article-title":"Secukinumab demonstrates high sustained efficacy and a favourable safety profile in patients with moderate-to-severe psoriasis through 5 years of treatment (SCULPTURE Extension Study)","volume":"32","author":"Bissonnette","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"5 Suppl. 1","key":"2023100520314718800_ljac040-B10","first-page":"AB2376","article-title":"Secukinumab withdrawal leads to loss of treatment responses in a majority of subjects with plaque psoriasis with retreatment resulting in rapid regain of responses: a pooled analysis of two phase 3 trials","volume":"74","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2023100520314718800_ljac040-B11","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.3390\/ijms18112427","article-title":"Treatment approaches to moderate to severe psoriasis","volume":"18","author":"Gisondi","year":"2017","journal-title":"Int J Mol Sci"},{"key":"2023100520314718800_ljac040-B12","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.jaad.2020.11.022","article-title":"Long-term efficacy and safety of ixekizumab: a 5-year analysis of the UNCOVER-3 randomized controlled trial","volume":"85","author":"Blauvelt","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"2023100520314718800_ljac040-B13","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s13555-020-00367-x","article-title":"Efficacy and safety of ixekizumab through 5 years in moderate-to-severe psoriasis: long-term results from the UNCOVER-1 and UNCOVER-2 phase-3 randomized controlled trials","volume":"10","author":"Leonardi","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"2023100520314718800_ljac040-B14","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1080\/09546634.2020.1782817","article-title":"Continuous treatment with guselkumab maintains clinical responses through 4 years in patients with moderate-to-severe psoriasis: results from VOYAGE 1","volume":"33","author":"Griffiths","year":"2022","journal-title":"J Dermatolog Treat"},{"key":"2023100520314718800_ljac040-B15","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1111\/bjd.13469","article-title":"Long-term efficacy and safety of ustekinumab, with and without dosing adjustment, in patients with moderate-to-severe psoriasis: results from the PHOENIX 2 study through 5 years of follow-up","volume":"172","author":"Langley","year":"2015","journal-title":"Br J Dermatol"},{"key":"2023100520314718800_ljac040-B16","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1111\/jdv.12046","article-title":"Long-term efficacy of ustekinumab in patients with moderate-to-severe psoriasis treated for up to 5 years in the PHOENIX 1 study","volume":"27","author":"Kimball","year":"2013","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100520314718800_ljac040-B17","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jaad.2017.06.153","article-title":"Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)","volume":"77","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"2023100520314718800_ljac040-B18","doi-asserted-by":"crossref","first-page":"e33-45","DOI":"10.1016\/j.jaad.2010.07.026","article-title":"Assessment of the long-term safety and effectiveness of etanercept for the treatment of psoriasis in an adult population","volume":"66","author":"Papp","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"2023100520314718800_ljac040-B19","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.jaad.2015.06.038","article-title":"Five-year analysis from the ESPRIT 10-year postmarketing surveillance registry of adalimumab treatment for moderate to severe psoriasis","volume":"73","author":"Menter","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"2023100520314718800_ljac040-B20","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1111\/jdv.13771","article-title":"Real-life 9-year experience with adalimumab in psoriasis and psoriatic arthritis: results of a single-centre, retrospective study","volume":"31","author":"Chiricozzi","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100520314718800_ljac040-B21","doi-asserted-by":"crossref","first-page":"222","DOI":"10.5021\/ad.2016.28.2.222","article-title":"The MARCOPOLO study of ustekinumab utilization and efficacy in a real-world setting: treatment of patients with plaque psoriasis in Asia-Pacific countries","volume":"28","author":"Youn","year":"2016","journal-title":"Ann Dermatol"},{"key":"2023100520314718800_ljac040-B22","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.jaad.2016.03.024","article-title":"Secukinumab long-term safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis","volume":"75","author":"Van de Kerkhof","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2023100520314718800_ljac040-B23","first-page":"67","article-title":"Continued treatment with secukinumab is associated with high retention or regain of response","volume":"182","author":"Augustin","year":"2020","journal-title":"Br J Dermatol"},{"key":"2023100520314718800_ljac040-B24","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1111\/jdv.16202","article-title":"Real-world data from a single Greek centre on the use of secukinumab in plaque psoriasis: effectiveness, safety, drug survival, and identification of patients that sustain optimal response","volume":"34","author":"Rompoti","year":"2020","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023100520314718800_ljac040-B25","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/bjd.19398","article-title":"Secukinumab 2-weekly vs. 4-weekly dosing in patients with plaque-type psoriasis: results from the randomized GAIN study","volume":"184","author":"Reich","year":"2021","journal-title":"Br J Dermatol"},{"key":"2023100520314718800_ljac040-B26","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.jaad.2017.10.012","article-title":"Characterization of disease burden, comorbidities, and treatment use in a large, US-based cohort: results from the Corrona Psoriasis Registry","volume":"78","author":"Strober","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"2023100520314718800_ljac040-B27","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/bjd.16102","article-title":"Safety, efficacy and drug survival of biologics and biosimilars for moderate-to-severe plaque psoriasis","volume":"178","author":"Egeberg","year":"2018","journal-title":"Br J Dermatol"},{"issue":"0","key":"2023100520314718800_ljac040-B28","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1111\/jdv.14200","article-title":"Characteristics of patients receiving ustekinumab compared with secukinumab for treatment of moderate-to-severe plaque psoriasis \u2013 nationwide results from the DERMBIO registry","volume":"31","author":"Egeberg","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljac040\/48518003\/ljac040.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/2\/198\/51903159\/ljac040.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/2\/198\/51903159\/ljac040.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T16:56:45Z","timestamp":1696525005000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/188\/2\/198\/6765238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,21]]},"references-count":28,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,10,21]]},"published-print":{"date-parts":[[2023,2,10]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljac040","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,2,1]]},"published":{"date-parts":[[2022,10,21]]}}}